

Reference:	FOI.10958.23
Subject:	Biologic medications within Dermatology
Date of Request:	14 February 2023

Requested:

Could you please tell me how many patients were treated in January 2023 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olumiant)
- Dupilumab (Dupixent)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)

Response:

Hywel Dda University Health Board (UHB) provides, within the table overleaf, the number of patients treated with the named biologic medications by the Dermatology Department during January 2023.

Medicine	Number
Abrocitinib (Cibinqo)	0
Baricitinib (Olumiant)	0
Dupilumab (Dupixent)	22
Tralokinumab (Adtralza)	*
Upadacitinib (Rinvoq)	0

Where the figure in the table has been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act (DPA) 2018/General Data Protection Regulations (GDPR) 2016, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 define personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.